Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials.

Thaçi, D; Jullien, D; Egeberg, A; Carrascosa, J M; Wu, J J; Pau-Charles, I; Gisondi, P

Thaçi, D; Jullien, D; Egeberg, A; Carrascosa, J M; Wu, J J; Pau-Charles, I; Gisondi, P.

Thaçi D; Institute and Comprehensive Centre for Inflammation Medicine, University of Lübeck, Lübeck, Germany.
Jullien D; Department of Dermatology, Edouard Herriot Hospital, Lyon, France.
Egeberg A; Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
Carrascosa JM; Department of Dermatology, Germans Trias i Pujol University Hospital (HUGTP), Autonomous University of Barcelona (UAB), Badalona, Spain.
Wu JJ; Dermatology Research and Education Foundation, Irvine, California, USA.
Pau-Charles I; Almirall R&D, Barcelona, Spain.
Gisondi P; Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.

J Eur Acad Dermatol Venereol ; 35(11): e709-e711, 2021 Nov.

Article in English | MEDLINE | ID: covidwho-1247231

Subject(s)

Psoriasis; Virus Diseases; Antibodies, Monoclonal, Humanized; Humans; Incidence; Psoriasis/drug therapy; Psoriasis/epidemiology; Severity of Illness Index; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Psoriasis / Virus Diseases Type of study: Observational study / Prognostic study / Reviews Limits: Humans Language: English Journal: J Eur Acad Dermatol Venereol Journal subject: Dermatology / Sexually Transmitted Diseases Year: 2021 Document Type: Article Affiliation country: Jdv.17427

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google